Medikonia Appointed as AmoyDx Distributor in Hong Kong and Macau

CENTRAL, Hong Kong - Feb. 1, 2018 - PRLog -- With the arrival of the first KRAS/NRAS Mutations Detection Kits at Hong Kong port, Medikonia Limited (Medikonia) announces today it has signed distributorship agreement with Amoy Diagnostics Co., Ltd. (AmoyDx) to bring its wide range of molecular diagnostics tests to Hong Kong and Macau.

"Precision medicine is a promising industry; it will help patients get right medications based on his/her genetic profile, saving dramatically for healthcare" said Joe Lai, Chief Executive Officer of Medikonia. "AmoyDx's molecular tests are reliable tools for oncologists to make right treatment decisions, bringing precision medicine concept into reality."

Paul Huang, International Business Director at AmoyDx added "Hong Kong has the best healthcare system in the world with the highest life expectancy. Our molecular diagnostics tests powered by proprietary ADx-ARMS and Super-ARMS technologies will help patients get right cancer drugs and increase the quality of lives. We are very pleased to align ourselves with a passionate partner like Medikonia to extend our global reach to Hong Kong and Macau."

ABOUT MEDIKONIA:  Established in 2015, Medikonia Limited, based in Hong Kong, is a leading distributor of molecular biology, life science, and clinical diagnostic, medical equipment throughout Hong Kong and Macau. For more about Medikonia, please visit www.medikonia.com

ABOUT AMOYDX: Amoy Diagnostics Co., Ltd. (AmoyDx) focuses on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS and Super-ARMS technologies, AmoyDx has a market-leading portfolio of molecular diagnostic kits including but not limited to EGFR, RAS, ALK, BRAF, PIK3CA and ROS1 testing kits, which were approved by CFDA and CE certified. For more about AmoyDx, please visit www.amoydiagnostics.com